Core Viewpoint - Vision Sensing Acquisition Corp. (VSAC) will have its securities suspended from trading on Nasdaq after October 25, 2024, due to a voluntary delisting request and failure to deposit required extension fees [2][3]. Group 1: Securities Suspension and Delisting - The Company notified Nasdaq on October 8, 2024, about the non-deposit of required extension fees and requested a voluntary delisting [2]. - Nasdaq will file a Form 25 with the U.S. Securities and Exchange Commission (SEC) to initiate the delisting process, which will take effect ten days after the filing [2]. Group 2: Liquidation and Redemption Amount - The per-share redemption price for the class A common stock is approximately $11.84, with payments scheduled for October 30, 2024 [3]. - The Company will retain $100,000 from the trust account for dissolution expenses and will pay $88,102 for taxes before distributing the redemption amount [3]. - As of October 18, 2024, there were 1,133,691 remaining public shares, and the trust account balance was approximately $13,427,746.07 [3]. Group 3: Redemption Process - Holders of public shares must present their share or unit certificates to receive the redemption amount, while beneficial owners in "street name" will not need to take action [4]. - There will be no redemption rights or liquidating distributions for the Company's warrants, which will expire worthless [4]. Group 4: Company Overview - Vision Sensing Acquisition Corp. is a Special Purpose Acquisition Company (SPAC) focused on acquiring vision sensing technologies, including hardware solutions, application software, and artificial intelligence [7].

Core Viewpoint - Vision Sensing Acquisition Corp. (VSAC) is unable to complete its initial business combination and will proceed with dissolution and liquidation due to the failure to deposit the required extension fee [1][3]. Group 1: Company Operations - The Sponsor, Vision Sensing LLC, did not deposit the necessary extension fee by October 3, 2024, preventing VSAC from extending the deadline for its initial business combination [1]. - As of October 18, 2024, the per-share redemption price for the class A common stock was approximately $11.92, with a total of about $13,515,848.07 in the trust account [5]. - The company will redeem 100% of the Offering Shares at a price based on the amount in the trust account, minus up to $100,000 for dissolution expenses [3][5]. Group 2: Delisting Process - On October 8, 2024, VSAC notified Nasdaq of its intention to seek a voluntary delisting due to the failure to deposit the required fees [2]. - Nasdaq is expected to file a Form 25 with the U.S. Securities and Exchange Commission (SEC) to initiate the delisting process, which will take effect ten days after the filing [2]. Group 3: Liquidation Details - Following the redemption of shares, the company will dissolve and liquidate, subject to the approval of remaining stockholders and the Board [3]. - The company will cease all operations except those necessary for winding up its business after October 21, 2024 [6].

Core Points - Vision Sensing Acquisition Corp. (VSAC) has announced an extension for its initial business combination deadline from October 3, 2024, to November 3, 2024 [1] - The company will deposit $51,016.10 into its trust account by July 3, 2024, as part of this extension [1] - This extension marks the sixth of up to six one-month extensions authorized under its amended certificate of incorporation [1][2] Company Overview - Vision Sensing Acquisition Corp. is a Special Purpose Acquisition Company (SPAC) focused on acquiring a private technology company [3] - EF Hutton, a division of Benchmark Investments, LLC, serves as the Capital Market Advisor, while ARC Group Limited acts as the Financial Advisor to VSAC [3]

Group 1 - Vision Sensing Acquisition Corp. has extended the deadline for its initial business combination from September 3, 2024, to October 3, 2024, by depositing $51,016.10 into its trust account [1][2] - This extension marks the fifth of up to six one-month extensions authorized under the company's amended and restated certificate of incorporation [1] - The company is a Special Purpose Acquisition Company (SPAC) focused on acquiring a private technology company [3] Group 2 - EF Hutton, a division of Benchmark Investments, LLC, is serving as the Capital Market Advisor to Vision Sensing Acquisition Corp. [3] - ARC Group Limited is acting as the Financial Advisor to the company [3]

Core Points - Vision Sensing Acquisition Corp. (VSAC) has announced an extension of the deadline for its initial business combination from September 3, 2024, to October 3, 2024 [1] - The company will deposit $51,016.10 into its trust account as part of this extension, and will issue a noninterest bearing, unsecured promissory note to its sponsor for the same amount [1][2] - This extension marks the fifth of up to six one-month extensions authorized under the company's amended certificate of incorporation [1] Company Overview - Vision Sensing Acquisition Corp. is a Special Purpose Acquisition Company (SPAC) focused on acquiring a private technology company [3] - EF Hutton, a division of Benchmark Investments, LLC, serves as the Capital Market Advisor, while ARC Group Limited acts as the Financial Advisor to VSAC [3]

Core Points - Vision Sensing Acquisition Corp. (VSAC) has mutually agreed to terminate its merger agreement with Mediforum Co., Ltd. due to the inability to complete the transaction within a reasonable timeframe [2] - VSAC has entered into a non-binding letter of intent with Convergence CT, Inc. (CCT) to pursue a business combination, where VSAC will acquire 100% of CCT's outstanding equity [3][4] - The total consideration for CCT's shareholders in the business combination is set at US$135 million, with an initial payment of US$110 million and additional earn-out shares based on performance [7][8] Company Overview - Convergence CT, Inc. specializes in smart hospital information systems and optimizing hospital workflows through proprietary technology, IoT, and AI integration [4][11] - CCT has over 20 years of experience in healthcare data integration, providing valuable global health insights to healthcare providers, life sciences companies, payers, and governments [4][11] - The management team of CCT is expected to continue leading the combined company post-transaction, which will trade on NASDAQ under a new ticker symbol [4][6] Transaction Details - The business combination will involve the formation of a new company in an offshore jurisdiction, which will serve as the publicly traded holding company for the combined entity [6] - The transaction is subject to customary closing conditions, including PCAOB-approved audits for CCT for the fiscal years ending December 31, 2022, and 2023 [10] - The initial board of directors for the surviving entity will consist of five directors, with a majority required to be independent under NASDAQ rules [9]

Company Overview - Vision Sensing Acquisition Corp. (VSAC) is a special purpose acquisition company (SPAC) focused on acquiring a private technology company [5] - Mediforum Co., Ltd is a leading Korean biotechnology company established in 2015, specializing in treatments for Alzheimer's disease and neuropathic pain [3] Business Combination Details - VSAC has extended the deadline for its initial business combination with Mediforum from August 3, 2024, to September 3, 2024 [1][2] - The company will issue a noninterest bearing, unsecured promissory note to its sponsor for $51,016.10 as part of the extension [1] - The Mediforum Business Combination Agreement was signed on January 12, 2024, indicating a formal agreement for the merger [2] Mediforum's Product Pipeline - Mediforum's flagship product, PM012, is in Phase 2b trials for Alzheimer's disease, with plans for Phase 3 trials in Korea and the U.S. [3] - The company is also developing MF018, which is in Phase 2 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and has plans for Phase 3 trials [3] Advisors and Legal Counsel - Norwich Capital Limited and American General Business Association & SME Overseas IPO Capital Group are acting as Lead Advisor and Co-Advisor for Mediforum [4] - Loeb & Loeb LLP is serving as US Legal Counsel, while Next Law LLP is the Korean Legal Counsel for Mediforum [4]

Company Overview - Vision Sensing Acquisition Corp. (VSAC) is a special purpose acquisition company (SPAC) focused on acquiring a private technology company [5] - Mediforum Co., Ltd is a leading Korean biotechnology company established in 2015, specializing in treatments for Alzheimer's disease and neuropathic pain [3] Business Combination Details - VSAC has extended the deadline for its initial business combination with Mediforum from August 3, 2024, to September 3, 2024 [1][2] - The company will issue a noninterest bearing, unsecured promissory note of $51,016.10 to its sponsor as part of the funding for this extension [1] - The Mediforum Business Combination Agreement was signed on January 12, 2024, indicating a formal agreement for the merger [2] Mediforum's Product Pipeline - Mediforum's flagship product, PM012, is in Phase 2b trials for Alzheimer's disease, with plans for Phase 3 trials in Korea and the U.S. [3] - The company is also developing MF018, which is in Phase 2 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and has plans for Phase 3 trials [3] Advisors and Legal Counsel - Norwich Capital Limited and American General Business Association & SME Overseas IPO Capital Group are acting as Lead Advisor and Co-Advisor for Mediforum [4] - Loeb & Loeb LLP is serving as US Legal Counsel, while Next Law LLP is the Korean Legal Counsel for Mediforum [4]

Core Points - Vision Sensing Acquisition Corp. (VSAC) is a Special Purpose Acquisition Company (SPAC) focused on acquiring a private technology company [5] - VSAC successfully migrated its listing from the Nasdaq Global Market to the Nasdaq Capital Market, effective July 19, 2024 [3][16] - Mediforum Co., Ltd, a leading Korean biotechnology company, is the target for VSAC's business combination, with a focus on enhancing the quality of life for patients with conditions like Alzheimer's disease [10] Compliance and Listing - On February 7, 2024, VSAC filed the outstanding 10-Q and regained compliance with Nasdaq Listing Rule 5250(c)(1) [1] - Following a staff determination letter from Nasdaq on January 17, 2024, VSAC appealed the decision to delist its securities and was granted a hearing scheduled for April 4, 2024 [7][17] - The Nasdaq Hearings Panel granted VSAC an extension to continue its listing, contingent upon transferring to the Capital Market by July 15, 2024 [8] Shareholder Actions - On July 12, 2024, VSAC confirmed it had enough public shareholders to meet the Nasdaq Capital Market Total Holders Requirement [18] - The conversion of 2,530,000 Series B shares into Series A shares on July 12, 2024, was part of the compliance strategy with the Market Value of Listed Securities Requirement [9] Business Combination - The Mediforum Business Combination Agreement requires VSAC to file a registration statement with the SEC, including a proxy statement for stockholder approval [12] - Mediforum is positioned to become the first Korean biotech company listed on NASDAQ, with ongoing clinical trials for its flagship product PM012 targeting Alzheimer's disease [10]

Company Overview - Vision Sensing Acquisition Corp. (VSAC) is a Special Purpose Acquisition Company (SPAC) focused on acquiring a private technology company [15] - Mediforum Co., Ltd is a leading Korean biotechnology company established in 2015, headquartered in Seoul, with a mission to enhance the quality of life for those facing conditions like Alzheimer's disease and neuropathic pain [14] Business Combination Details - VSAC has entered into a Business Combination Agreement with Mediforum, extending the deadline to complete the initial business combination from July 3, 2024, to August 3, 2024 [6][13] - The sponsor, Vision Sensing, LLC, will deposit $51,016.10 into VSAC's trust account as part of the extension, and VSAC will issue a non-interest bearing, unsecured promissory note for the same amount [13] Product Pipeline - Mediforum's flagship product, PM012, is currently in Phase 2b trials for Alzheimer's disease, with plans for Phase 3 trials in Korea and the U.S. [14] - Mediforum is also developing MF018, which is in Phase 2 for Chemotherapy-Induced Peripheral Neuropathy and has plans for Phase 3 trials, with applications for Diabetic Peripheral Neuropathy [14] Market Position and Future Plans - Mediforum aims to become the first Korean biotech company listed on NASDAQ, emphasizing its commitment to technology, innovation, and transformative healthcare solutions [14]